Globus/NuVasive: Spinal-Device Merger Could Give Doctors Fewer Operating Options, Some Surgeons Say

Published on Jul 07, 2023

Globus Medical’s (GMED) proposed $3.1 billion acquisition of rival NuVasive (NUVA) could accelerate a market trend that has resulted in fewer choices of spinal devices and operating techniques, some surgeons told The Capitol Forum. The surgeons said that hospitals seeking discounts on supplies and equipment are increasingly entering into contracts and arrangements with suppliers that […]

FTC v. Meta: Trial That Could Break Up Social Network Giant to Show Clashing Views of Online Ecosystem

After a wait of more than four years, the trial of the FTC’s antitrust case against Meta begins today, pitting an enforcer bent on reining in Big Tech against a company defending past acquisitions...

Apr 14, 2025 Read Now >

ADNOC/Covestro: EU Sets Sights on Deal in Fresh Foreign Subsidy Rules Test

The European Commission is poised to use its only in-depth foreign subsidies case as a blueprint as it weighs potential concessions from UAE oil giant ADNOC, ahead of a €14.7 billion deal filing...

Apr 11, 2025 Read Now >

LiveRamp: Company Hosts Marketplace Selling Datasets that Target Millions of Americans Based on Sensitive Information, Military Status

Data broker LiveRamp Holdings, Inc. (RAMP) operates a vast digital marketplace that exchanges the personal information of hundreds of millions of individuals grouped into highly specific audience...

Apr 08, 2025 Read Now >

Globus/NuVasive: Spinal-Device Merger Could Give Doctors Fewer Operating Options, Some Surgeons Say

RELATED ARTICLES | Editor’s picks

FTC v. Meta: Trial That Could Break Up Social Network Giant to Show Clashing Views of Online Ecosystem

ADNOC/Covestro: EU Sets Sights on Deal in Fresh Foreign Subsidy Rules Test

LiveRamp: Company Hosts Marketplace Selling Datasets that Target Millions of Americans Based on Sensitive Information, Military Status

FILTER BY

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.